Loading clinical trials...
Loading clinical trials...
Compassionate Use of Combination Therapy with Asparaginase and Pembrolizumab in Patients with Nasopharyngeal Carcinoma
Conditions
Interventions
Anti-PD1
asparaginase
Locations
1
Taiwan
Chang Gung Memorial Hospital
Taoyuan, Taiwan
Start Date
August 1, 2023
Primary Completion Date
April 30, 2024
Completion Date
August 1, 2024
Last Updated
November 7, 2024
NCT07459296
NCT07340515
NCT06982300
NCT07085988
NCT07072143
NCT06870435
Lead Sponsor
Chang Gung Memorial Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions